Compare GSK plc (GSK) vs Toronto-Dominion Bank (TD) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

TD trades at $123.51, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the company maintains a strong net income margin of 23.38%. A dividend of $1.12 per share is scheduled for payment on July 31, 2026.

The outlook for TD is positive, supported by earnings momentum and analyst confidence, though risks include volatile cash flows from operations and rising debt levels. The stock's current valuation at a P/E of 20.8 appears reasonable relative to growth, positioning it as a candidate for long-term dividend growth despite near-term overbought technical conditions.